INTRODUCTION {#s1}
============

Bladder cancer (BC) ranks as the ninth most frequently-diagnosed cancer worldwide, with an estimation of 430, 000 new cases diagnosed in 2012 \[[@R1]\]. Stage 1 and grade 3 (T1G3) bladder cancer is pathologically classified into non-muscle invasive bladder cancer (NMIBC), which is characterized by a high risk of recurrence and progression after the treatment of transurethral resection of bladder tumor (TURB) alone, with a recurrence rate of 50% to 70% and a tumor progression rate of 25% to 50% \[[@R2]\]. Due to its high propensity to recur and progress to muscle invasive disease, T1G3 BC is considered as the most challenging form of NMIBC, and reportedly, its long-term death rate can be as high as 34% \[[@R3]\]. Therefore, there is a clear need for predictive markers of recurrence, progression and survival in patients with T1G3 BC. In the past two decades, many biomarkers, for example, the gene expression signatures of patients, have been proposed for oncologic outcomes prediction in BC \[[@R4], [@R5]\]. However, the power of these predictive biomarkers is still insufficient to meet the clinic needs.

Recently, there has been increasing interest in the prognostic role of hematologic biomarkers in patients undergoing TURB. Neutrophil-lymphocyte ratio (NLR) has been repeatedly reported as an efficient biomarker to predict oncologic outcomes in patient undergoing TURB for NMIBC \[[@R6], [@R7]\]. Other hematologic biomarkers, including lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio (PLR), have also been suggested \[[@R7], [@R8]\]. While attention is mainly focused on biomarkers that reflect the interaction between systemic inflammatory response and tumor, to date, the prognostic role of hemoglobin-platelet ratio has not been studied in T1G3 BC. Its consistency and significance as prognosticator are still unclear in T1G3 BC.

In this study, we aim to determine whether HPR is an independent predictor of disease progression, OS and CSS in T1G3 BC patients who underwent TURB.

RESULTS {#s2}
=======

Clinicopathological characteristics of patients {#s2_1}
-----------------------------------------------

Data of the clinicopathological variables of the patients are summarized in Table [1](#T1){ref-type="table"}. The mean follow-up for patients in this retrospective study was 39 months (IQR: 16-49). Of the 457 patients, 27.4% (*n* = 125) patients had cancer recurrence, and 9.6% (*n* = 44) progressed after initial TURB. The number of all-cause and cancer-specific death were 86 (18.8%) and 51 (11.2%), respectively. The median values of hematological markers were 131 for hemoglobin (IQR: 117-148), 232 for platelet counts (IQR: 188-316), and 0.625 for HPR (IQR: 0.283-0-802), respectively. The optimal cut-off value of HPR, which was 0.615 (Figure [1](#F1){ref-type="fig"}), was determined by receiver operating characteristic (ROC) curve. Similarly, the cut-off values of hemoglobin, platelet counts, NLR, PLR and LMR were 125, 240, 2.3, 128 and 3.2, respectively. According to the preoperative HPR status (\< 0.615 versus ≥ 0.615), patients in the cohort were dichotomized. As shown in Table [2](#T2){ref-type="table"}, no significant differences in the demographic variables including sex, smoking history, BMI, DM and hypertension were observed between the two groups (All *P* \> 0.05). Furthermore, there were no primary differences in number of tumor, tumor size, NLR, PLR, LMR between the two groups (All *P* \> 0.05).

###### Clinicopathological variables of the 457 patients with T1G3 bladder cancer in the study

  Variables                        
  -------------------------------- ----------------------
  Age, years                       66 (54--74)
  Gender, *n* (%)                  
   Male                            355 (77.7)
   Female                          102 (22.3)
  Smoking history, *n* (%)         171 (37.4)
  BMI, kg/cm^2^                    25.3 (21.8--27.5)
  DM, *n* (%)                      88 (19.3)
  Hypertension, *n* (%)            220 (48.1)
  Multifocal, *n* (%)              
   Yes                             185 (40.5)
   No                              272 (59.5)
  Tumor size (cm), *n* (%)         
   \< 3                            322 (70.5)
   ≥ 3                             135 (29.5)
  Oncological outcomes, *n* (%)    
   Recurrence                      125 (27.4)
   Progression                     44 (9.6)
   All-cause mortality             86 (18.8)
   Cancer-specific mortality       51 (11.2)
  Hematological markers, *n* (%)   
  Hemoglobin, g/l                  131 (117--148)
   Platelet counts, ×10^3^/μl      232 (188--316)
   HPR                             0.625 (0.283--0.802)
   NLR                             1.96 (1.45--2.68)
   PLR                             121.6 (89.7--192.4)
   LMR                             2.98 (2.33--3.87)
  Follow-up duration (mon)         39 (16--49)

Abbreviations: T1G3, stage 1 and grade 3; BMI, body mass index; DM, diabetes mellitus; HPR, hemoglobin-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

![Receiver operating characteristic curve analysis of the ability of hemoglobin-platelet ratio (HPR) to discriminate for overall survival in overall population of T1G3 bladder cancer patients\
It suggests that HPR predicts OS with a sensitivity of 74.7% and a specificity of 57.8% (AUC = 0.680; 95% CI = 0.605--0.755; *P* \< 0.001).](oncotarget-09-18627-g001){#F1}

###### Comparing the clinicopathological variables according to the preoperative HPR status in the 457 patients with T1G3 bladder cancer

  ------------------------------------------------------------------------------------------
  Variables                      HPR ≥ 0.615\             HPR \< 0.615\          *P* value
                                 (n = 277)                (n = 180)              
  ------------------------------ ------------------------ ---------------------- -----------
  Age, years                     59 (52--65)              68 (59--73)            \< 0.001

  Gender, n (%)                                                                  

   Male                          217 (78.3)               138 (76.7)             0.675

   Female                        60 (21.7)                42 (23.3)              

  Smoking history, n (%)                                                         

   Yes                           94 (33.9)                77 (42.8)              0.056

   No                            183 (66.1)               103 (57.2)             

  BMI, kg/cm^2^                  24.3 (22.5--26.7)        25.8 (22.9--26.6)      0.069

  DM, n (%)                                                                      

   Yes                           46 (16.6)                42 (23.3)              0.075

   No                            231 (83.4)               138 (76.7)             

  Hypertension, n (%)                                                            

   Yes                           126 (45.5)               94 (52.2)              0.159

   No                            151 (54.5)               86 (47.8)              

  Multifocal, n (%)                                                              

   Yes                           101 (36.5)               74 (41.1)              0.318

   No                            176 (63.5)               106 (58.9)             

  Tumor size (cm), n (%)                                                         

   \< 3                          202 (72.9)               120 (66.7)             0.152

   ≥ 3                           75 (27.1)                60 (33.3)              

  Oncological outcomes, n (%)                                                    

   Recurrence                    67 (24.2)                58 (32.2)              0.060

   Progression                   19 (6.9)                 25 (13.9)              0.013

   All-cause mortality           38 (12.3)                48 (29.9)              \< 0.001

   Cancer-specific mortality     22 (7.9)                 29 (16.1)              0.008

  Hematological marker, n (%)                                                    

   Hemoglobin (g/l)              138 (121--157)           121 (103--136)         0.016

   Platelet counts (×10^3^/μl)   221 (183--274)           237 (190--306)         0.058

   HPR                           0.657 (0.304 -- 0.864)   0.562 (0.237--0.715)   \< 0.001

   NLR                           1.92 (1.37--2.47)        2.06 (1.58--2.76)      0.189

   PLR                           116 (81.3--179.6)        127 (94.3--202.5)      0.273

  LMR                            3.11 (2.52--3.96)        2.82 (2.21--3.74)      0.481

  Follow-up duration (mon)       37 (14 -- 43)            40 (17--45)            0.146
  ------------------------------------------------------------------------------------------

Abbreviations: T1G3, stage 1 and grade 3; BMI, body mass index; DM, diabetes mellitus; HPR, hemoglobin-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

Correlation between hematological markers and prognosis of the patients with T1G3 bladder cancer {#s2_2}
------------------------------------------------------------------------------------------------

We used Kaplan-Meier survival analysis to identify the associations of hematological markers (hemoglobin, platelet counts and HPR) with oncological outcomes. Notably, low HPR \< 0.615) is associated with worse PFS, but not low hemoglobin (\< 125) and elevated platelet counts (\> 240) (Figure [2A](#F2){ref-type="fig"}). Moreover, low HPR, low hemoglobin and elevated platelet counts were significantly associated with poor OS (Figure [2B](#F2){ref-type="fig"}). In addition, low HPR and low hemoglobin, but not elevated platelet counts, were independently associated with poor CSS estimates in the cohort (Figure [2C](#F2){ref-type="fig"}). Interestingly, no significant difference was found in RFS rates according to hemoglobin, platelet counts or HPR ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), and either in RFS, PFS, OS or CSS rates in terms of the hematologic biomarker NLR, PLR or LMR (data not shown).

![Kaplan-Meier survival estimates for comparing\
(**A**) progression-free, (**B**) overall and (**C**) cancer specific survivals according to the preoperative status of (a) hemoglobin-platelet ratio (HPR), (b) hemoglobin, and (c) platelet counts, respectively in the stage 1 and grade 3 (T1G3) bladder cancer patients who underwent transurethral resection of the bladder (TURB). Statistical differences between the two groups were compared by using the log-rank test.](oncotarget-09-18627-g002){#F2}

The primary predictors of progression and survival outcomes {#s2_3}
-----------------------------------------------------------

We furthermore performed multivariate Cox regression analysis to identify the predictors of oncological outcomes in patients with T1G3 bladder cancer who underwent TURB. In univariate analysis, NLR, PLR and LMR showed marginal associations with PFS, OS and CSS, however, not statistically significant. The multivariate analysis showed that low HPR was a predictor for OS (HR = 1.27, 95% CI 0.81--1.75), and so was the age (HR = 1.24, 95% CI 1.03--1.43), low hemoglobin (HR = 1.20, 95% CI 0.79--1.84), and elevated platelet counts (HR = 1.07, 95% CI 0.72--1.32). The predictive ability of HPR for OS was also supported by ROC curve (AUC = 0.680; 95% CI = 0.605--0.755; *P* \< 0.001). The multivariate analysis also revealed that low hemoglobin was a significant predictor for CSS (HR = 1.08, 0.68--1.82). More importantly, low HPR was identified as an independent predictor for PFS (HR = 1.16, 0.97--1.49) and CSS (HR = 1.14, 0.87--1.78), indicating that decease in HPR would increase the risk of progression and cancer-specific mortality (Table [3](#T3){ref-type="table"}).

###### Univariate and multivariate analyses for PFS, OS and CSS according to clinicopathological variables in T1G3 bladder cancer patients underwent TURB

  Variables                          Univariate   Multivariate                                      
  ---------------------------------- ------------ -------------- ---------- ---------- ------------ -----------
  **PFS**                                                                                           
   Hemoglobin (g/l)                                                                                 
   ≥ 125                             1                                      1                       
   \< 125                            1.08         0.70--1.87     0.037      1.03       0.57--2.14   0.290
   Platelet counts (×10^3^/μl)                                                                      
   \< 240                            1                                      1                       
   ≥ 240                             1.21         0.78--1.47     0.016      1.02       0.65--1.53   0.110
   **HPR**                                                                                          
   ≥ 0.615                           1                                      1                       
   \< 0.615                          1.31         1.02--1.46     0.003      **1.16**   0.97--1.49   **0.033**
   NLR                               1.16         0.96--1.32     0.053      1.11       0.91--1.47   0.131
   PLR                               1.04         0.82--1.28     0.061      1.17       0.74--1.33   0.461
   LMR                               1.09         0.87--1.29     0.073      1.24       0.62--1.56   0.533
  **OS**                                                                                            
   **Age (year)**                                                                                   
   \< 65                             1                                      1                       
   **≥ 65**                          1.25         1.10--1.29     \< 0.001   **1.24**   1.03--1.43   **0.026**
   **Hemoglobin (g/l)**                                                                             
   ≥ 125                             1                                      1                       
   **\< 125**                        1.28         0.89--1.69     0.007      **1.20**   0.79--1.84   **0.028**
   **Platelet counts (×10^3^/μl)**                                                                  
   \< 240                            1                                      1                       
   **≥ 240**                         1.18         0.81--1.33     0.009      **1.07**   0.72--1.32   0.038
   **HPR**                                                                                          
   ≥ 0.615                           1                                      1                       
   **\< 0.615**                      1.22         0.93--1.61     0.002      **1.27**   0.81--1.75   **0.030**
   NLR                               2.13         1.43--2.89     0.059      1.83       1.13--3.02   0.241
   PLR                               1.85         1.21--2.67     0.066      1.45       1.03--2.84   0.378
   LMR                               1.63         0.88--2.04     0.070      1.02       0.64--2.29   0.409
  CSS                                                                                               
   Hemoglobin (g/l)                                                                                 
   ≥ 125                             1                                      1                       
   **\< 125**                        1.32         1.08--1.69     0.004      **1.08**   0.68--1.82   **0.041**
   Platelet counts (×10^3^/μl)                                                                      
   \< 240                            1                                      1                       
   ≥ 240                             1.14         0.68--1.51     0.031      1.06       0.31--2.13   0.083
   **HPR**                                                                                          
   ≥ 0.615                           1                                      1                       
   \< 0.615                          1.23         1.04--1.47     \< 0.001   **1.14**   0.87--1.78   **0.029**
   NLR                               2.37         1.87--2.89     0.056      1.99       1.53--2.97   0.190
   PLR                               2.02         1.72--2.59     0.063      1.89       1.44--2.76   0.177
   LMR                               1.88         1.42--2.47     0.067      1.55       1.31--2.55   0.216

Abbreviations: PFS, progression-free survival; OS, overall survival; CSS, cancer-special survival; TURB, transurethral resection of bladder tumor; HR, hazard ratio; CI, confidence interval; T1G3, stage 1 and grade 3; HPR, hemoglobin-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.

DISCUSSION {#s3}
==========

Recently, there has been increasing interest in the prognostic role of hematologic biomarkers in patients with bladder cancer. NLR has been highlighted as an efficient biomarker to predict oncologic outcomes in patients with bladder cancer \[[@R9]--[@R11]\]. Other biomarkers, including LMR and PLR, have also been reported \[[@R12], [@R13]\]. As a matter of fact, most of the biomarkers take advantage of the leukocyte parameters, and the prognostic role of hemoglobin level and platelet count have not been clearly defined. However, the number of studies exploring the prognostic role of hemoglobin and platelet level has been increasing \[[@R12], [@R14]--[@R18]\]. Previously, Sejima *et al*. \[[@R19]\] reported that hemoglobin level was an independent predictor of CSS (HR = 0.81). Grimm *et al*. \[[@R8]\] also observed that hemoglobin (\< 13.4g/dl) was an independent prognostic parameter regarding OS and CSS (HR = 0.60, HR = 0.60). In a study by Hara *et al*. which enrolled 254 patients with bladder cancer who underwent RC, hemoglobin concentration was shown to be significantly associated with OS (HR = 0.93, Age \< 75; HR = 8.61, Age \> 75). Most recently, a meta-analysis involved 6 independent studies with 4447 patients provided the data showing that a higher hemoglobin level was associated with decreased disease (DR), all-cause mortality (ACM) and cancer-specific mortality (CSM) (HR = 0.95, HR = 0.90, HR = 0.90) \[[@R20]\]. With regard to platelet count, Moschini *et al*. \[[@R21]\] revealed that platelet count was significantly related to OS (HR = 1.64).

Although much attention has been drawn to the prognostic role of hemoglobin and platelet level in bladder cancer, few studies evaluated the performance of these biomarkers in patients with NMIBC, particularly T1G3 bladder cancer who underwent TURB. Further, there had been no report focusing on the relationship between preoperative HPR and prognosis of T1G3 bladder cancer patients. Thus, in the present study, we examined the associations of a set of hematologic markers (hemoglobin, platelet count and HPR) with the survival outcomes in a cohort consisting of 457 patients with T1G3 bladder cancer who underwent TURB. We show that preoperative HPR and hemoglobin level are independently associated with OS and CSS. Moreover, HPR is significantly related to PFS, and preoperative HPR is an independent prognostic factor indicating progression and mortal outcome in T1G3 bladder cancer patients undergoing TURB. NLR, LMR and PLR are well-characterized prognostic biomarkers in patients with bladder cancer. However, in our cohort, NLR, LMR and PLR showed no significant associations with survival outcomes when patients were grouped based on HPR status. More independent and multicenter-based studies are anticipated to access the prognostic value of the lymphocyte-related parameters in T1G3 bladder cancer.

With the finding of concomitant anemia and thrombocytosis in cancer patients, the underlying molecular mechanisms are also being investigated. Gakis and his colleagues observed that the degree of hematological disorders was often associated with more aggressive diseases \[[@R22]\]. One possible mechanism for this observation is that growing tumors induce thrombocytosis by secretion of growth factors and cytokines. Interleukin-6 (IL-6), which can be produced by malignant tumors, is able to stimulate platelet production. IL-6 and tumor necrosis factor-α (TNF-α) are also important cytokines for the development of tumor-induced anemia. These two cytokines may play a role in shortening erythrocyte half-life and reducing iron utilization and Epo production \[[@R23]\]. GATA-2, which is a transcription factor in hematopoietic progenitor cells and usually acts via interaction with GATA-1, is overexpressed in early immature hematopoietic progenitors to ensure their maintenance and proliferation. Overexpression of GATA-2 also can lead to increased platelet production and inhibition of erythrocyte differentiation \[[@R24], [@R25]\]. In tumor microenvironment, the increased platelets can affect angiogenesis by releasing vascular endothelial growth factor (VEGF) \[[@R26]\], which plays an important role in the progression of bladder cancer \[[@R27]\]. Besides, the aggregation of tumor cells with platelets can protect them from the natural killer (NK) cells of the host immune system \[[@R28]\], and platelets promote the adhesion of tumor cells to endothelial cells, which is a necessary step in the process of extravasation \[[@R29]\]. In addition to the increased platelet production, cancer--associated anemia causes hypoxia and induces upregulation of hypoxia-inducible factor-1α. This leads to the upregulation of genes involved in angiogenesis which inhibit apoptosis \[[@R30]\] and increase cancer cell transmission \[[@R31]\]. Moreover, anemia stimulates the release of VEGF \[[@R32]\] which promotes angiogenesis and increases the biological invasiveness of the tumor. Taken together, multiple lines of evidence suggest a profound impact of cancer-associated anemia and thrombocytosis in tumor development, and also implicate a link between the hematologic biomarkers and cancer prognosis.

Certainly, we are aware of the potential limitations that are associated with our retrospective study at a single center, for example, a potential selection bias on patients. In this study, we mainly focused on the preoperative hematologic markers. Nonetheless, these markers may not fully represent the dynamic changes of HPR. Further, the cut-off values of preoperative hematologic markers were adopted based on ROC curve analysis, and we realize that our cut-off values are not consistent with those of other studies. We speculate that the different cut-off values may reflect the inherent differences among those independent study populations, such as distinct genetic and environment backgrounds.

In conclusion, we have identified that preoperative HPR is significantly associated with PFS, OS and CSS in T1G3 bladder cancer patients who underwent TURB. Our study indicates that preoperative HPR can be taken into account as a factor predictive of oncological outcomes for T1G3 bladder cancer, particularly disease progression and mortality outcomes.

MATERIALS AND METHODS {#s4}
=====================

We retrospectively reviewed 457 cases in which patients were diagnosed with T1G3 bladder cancer and underwent TURB from April 2009 to December 2014 at the Second Hospital of Tianjin Medical University. Pathological staging and grading of each tumor were determined according to the International Society of Urological Pathology 1998/World Health Organization 2004 classification. All patients were followed up retrospectively through hospital records and telephone interviews with either the patients or their close relatives. Histological examination was evaluated by two experienced genitourinary pathologists in our institute. All patients were initially treated with TURB. Tumor was pathologically diagnosed as T1G3 and with no carcinoma *in situ*. And all serum parameters were obtained from the routine preoperative test results of the patients. We excluded patients with a short-term follow up period (less than six months after TURB) and those with systemic inflammation.

This study was conducted in accordance to the Declaration of Helsinki and its amendments and approved by the local Ethics Committee of the Second Hospital of Tianjin Medical University.

We collected clinical and pathological data, which included age, gender, smoking history, body mass index (BMI), diabetes mellitus (DM), hypertension, hemoglobin (g/l), platelet counts (×10^3^/μl), preoperative HPR, the number and size of tumors, and the oncological outcomes including recurrence, progression, all-cause mortality and cancer-specific mortality. The HPR was calculated based on the hemoglobin and platelet counts (HPR = hemoglobin/platelet counts). The cut-off values of the HPR, hemoglobin and platelet counts were determined with receiver operating characteristic (ROC) curve with the best accuracy (the greatest sensitivity and specificity) \[[@R33]\]. Median and interquartile range (IQR) were calculated for continuous variables.

Urine cytology and cystoscopy were performed at 3-months interval for a period of the first 2 years after the initial TURB. Then, cystoscopy was conducted semiannually until the fifth year and annually thereafter. Bladder biopsy was conducted when necessary. Computed tomography scan was performed every year to assess the status of patients. During the follow-up, the end point of patients in the study was the time when bladder cancer recurrence and tumor progression were histologically confirmed, and the time of dead and the latest visit.

Statistical analysis {#s4_1}
--------------------

The outcome measures were RFS, PFS, OS and CSS evaluated in months from the date of TURB. The Kaplan-Meier survival analysis was conducted to evaluate progression and survival outcomes, and differences of the curves were examined by log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model to determine the independent predictors of various oncological outcomes. All statistical analysis was performed using SPSS 22.0 version statistical software (IBM, Armonk, New York, USA) and GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA). The two-sided *p*-value \< 0.05 indicates a statistically significant difference.

SUPPLEMENTARY MATERIALS FIGURES {#s5}
===============================
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